Alumis is a biotech developing immune-system drugs, aiming to treat autoimmune diseases with a TYK2 inhibitor and an antibody for thyroid eye disease.
No revenue yet; 2025 annual revenue was USD 0.02B, with a net loss of USD 0.24B and a negative net margin, funded by prior rounds. Money comes from R&D losses, not product sales.
Pipeline early stage, no approved product, rival drugs from Bristol-Myers Squibb (deucravacitinib) and AbbVie already treat psoriasis. Patents may be only barrier—but market advantage is unproven against larger, funded competitors. Level: eroding.
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
